Abstract
Several lines of evidence have indicated that free radicals may play a role in the pathophysiology of tardive dyskinesia (TD) (reviewed in Andreassen and Jorgensen, 2000). NAD(P)H: quinone oxidoreductase (NQO1) is an important enzyme in the human body that counteracts the oxidative stress-induced neuronal injury caused by the toxic free radicals such as dopamine-semiquinones. Taking the possible genetic predisposition to TD into account (Yassa and Ananth, 1981), the NQO1 gene is a good candidate gene that may confer increased susceptibility to TD. Based on this hypothesis, Pae et al. (2004) reported a significant association between the Pro187Ser polymorphism in the NQO1 gene and TD. In the present study, we attempted to replicate the findings of Pae et al. (2004) with the same polymorphism in 222 Japanese patients with schizophrenia. No significant difference was detected between patients with and without TD in the allelic distribution (χ2=0.070, d.f.=1,p=0.795) and in the genotypic distribution (χ2=0.910,d.f.=2,p=0.657). In addition, there was no significant difference in terms of total Abnormal Involuntary Movement Scale scores among the three genotype groups (p=0.49). Our results suggest that the NQO1 gene polymorphism does not confer an increased risk of TD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andreassen O. A. and Jorgensen H. A. (2000) Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog. Neurobiol. 61, 525–541.
Adler L. A., Peselow E., Rotrosen J., et al. (1993) Vitamin E treatment of tardive dyskinesia. Am. J. Psychiatry 150, 1405–1407.
Bai Y. M., Yu S. C., and Lin C. C. (2003) Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controller study. J. Clin. Psychiatry 64, 1342–1348.
Barrett J. C., Fry B., Maller J., and Daly M. J. (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263–265.
Bischot L., Van den Brink G., and Porsius A. J. (1993) Vitamin E in extrapyramidal disorders. Pharm. World Sci. 15, 146–150.
Drukarch B. and van Muiswinkel F. L. (2000) Drug treatment of parkinson's disease. Biochem Pharmacol. 59, 1023–1031.
Glazer W. M. (2000) Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J. Clin. Psychiatry 61 (Suppl 4), 21–26.
Guy W. (1976) Abnormal involuntary movement scale (AIMS), in US Department of Health, Education and Welfare: ECDEU Assessment Manual for Psychopharmacology, revised, US DWEW Publication, Washington, DC, pp. 534–537.
Hori H., Ohmori O., Matsumoto C., et al. (2003) NAD(P)H: quinone oxidoreductase (NQO1) gene polymorphism and schizophrenia. Psychiatr. Res. 118, 235–239.
Hori H., Ohmori O., Shinkai T., et al. (2000) Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacogy 23, 170–177.
Kappus H. and Sies H. (1981) Toxic drug effects assoclated with oxygen metabolism: redox cycling and lipid peroxidation. Experientia 37, 1233–1241.
Liou Y. J., Wang Y. C., Lin C. C., et al. (2005) Association analysis of NAD(P)H: quinone oxidoreductase (NQO1) Pro187Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan. Int. J. Neuropsychopharmacol. 8, 483–486.
Lohr J. B. and Caligiuri M. P. (1996) A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J. Clin. Psychiatry 57, 167–173.
Lohr J. B., Kuczenski R., Bracha H. S., Moir M., and Jeste D. V. (1990) Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol. Psychiatry 28, 535–539.
Pae C. U., Yu H. S., Kim J. J., et al. (2004) Quinone oxidoreductase (NQO1) gene polymorphism (607C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia. Int. J. Neuropsychopharmaco. 7, 495–500.
Shale H. and Tanner C. (1996) Pharmacologicaloptions for the management of dyskinesia. Drugs 52, 849–860.
Sham P. C. and Curtis D. (1995) Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann. Hum. Genet. 59, 97–105.
Schooler N. R. and Kane J. M. (1982) Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry 39, 486–487.
See R. E. (1991) Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to acute challenge with raclopride. Neurosci. Lett. 129, 265–268.
The International HapMap Consortium. (2003) The International HapMap Project. Nature 426, 789–796.
Toru M. (1983) Seishinbunretsubyo no yakuri (Pharmacology in schizophrenia), Chu-gai Igakusha Co., Tokyo.
Traver R. D., Horikoshi T., Danenberg K. D., et al. (1992) NAD(P)H: quinone oxidoreductase gene expression in human carcinoma cells: characterization of amutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res. 52, 797–802.
Traver R. D., Siegel D., Beall H. D., et al. (1997) Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br. J. Cancer 75, 69–75.
Tsai G., Goff D. C., Chang R. W., et al. (1998) Markers glutamatergic neurotransmission and oxidative stress associated tardive dyskinesia. Am. J. Psychiatry 155, 1207–1213.
Yassa R. and Ananth J. (1981) Familial tardive dyskinesia. Am. J. Psychiatry 138, 1618–1619.
Zhang Z., Zhang X., Hou G., Sha W., and Reynolds G. P. (2002) The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. J. Psychiatr. Res. 36, 317–324.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hori, H., Shinkai, T., Matsumoto, C. et al. No association between a functional NAD(P)H. Neuromol Med 8, 375–380 (2006). https://doi.org/10.1385/NMM:8:3:375
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/NMM:8:3:375